HOME >> BIOLOGY >> NEWS
Award winning researchers reveal potential new role for Glivec

Geneva, Switzerland: Imatinib or Glivec as it also known looks as if it may become an effective treatment for yet another type of cancer.

Consultant medical oncologist Dr. Grant McArthur told a news briefing today (Wednesday 29 September) that a Phase II study by an international team has shown that the drug is active against a rare type of cancer called dermatofibrosarcoma protuberans (DFSP) a malignant tumour that occurs in the second layer of the skin (the dermis)[1].

He said that complete control of the disease was achieved in eight out of 10 patients in a Phase II trial either through imatinib alone or imatinib plus surgery. The research team are preparing to present their findings to regulatory bodies for approval for imatinib's use as a treatment for unresectable DFSP when it exhibits a particular genetic profile.

The study, presented at the EORTC-NCI-AACR[2] Symposium on Molecular Targets and Cancer Therapeutics in Geneva, was selected as a proffered paper by the scientific board of the EORTC-NCI-AACR and also won an award from the Fondation Nelia et Amadeo Barletta (FNAB)[3], a foundation devoted to supporting worldwide translational research aimed at individualising therapeutics. The award is being presented today to Dr. McArthur, the lead researcher, by Professor Esteban Cvitkovic, president of the foundation's scientific board.

Dr McArthur, who is head of the Molecular Oncology and Translational Research Laboratories at the Peter McCallum Cancer Centre in Melbourne, Australia, said that the decision to try imatinib in the treatment of DFSP arose from pioneering research from another team published in 1997[4] . This had shown that a gene called the platelet-derived growth factor receptor B (PDGFB) was re-arranged in DFSP, involving a translocation between chromosomes 17 and 22.

"It was intuitive to try imatinib in the disease because this translocation results in over expression of PDGFB and imatinib is an inhi
'"/>

Contact: Margaret Willson
m.willson@mwcommunications.org.uk
41-227-612-205
European Organisation for Research and Treatment of Cancer
29-Sep-2004


Page: 1 2 3

Related biology news :

1. Gladstone investigator Mike McCune wins prestigious NIH Directors Pioneer Award
2. UT Southwestern biochemist honored with NIH Directors Pioneer Award
3. UMaine anthropologist wins Solon T. Kimball Award
4. Secretary of Energy announces seven E.O. Lawrence Award Winners
5. Martin Saunders to receive the James Flack Norris Award
6. Berkeley Lab soil scientist Margaret Torn receives Presidential Early Career Award
7. NJIT professor receives Presidential Award for breakthrough research with adult stem cells
8. Second call for proposals for the European Young Investigator Award
9. Virginia Tech professor honored with DeLaval Award
10. Institute for OneWorld Health nominated for the 2004 World Technology Awards
11. EURYI Award given for the first time to 25 young European researchers

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/4/2019)... ... 2019 , ... Catalent Pharma Solutions, the leading global provider ... products, today announced that it will host a roundtable session at the World ... Hill, Maryland, on April 10-12, 2019. , On Thursday, April 11 at 3:30 ...
(Date:4/1/2019)... ... April 01, 2019 , ... ... Characterizing Skin Related Conditions” by the US Patent and Trademark Office on January ... an invention by uBiome collaborators Dr. Zachary Apte, Dr. Daniel Almonacid, Dr. ...
(Date:3/29/2019)... ... March 29, 2019 , ... RoosterBio, Inc, ... attend the Society for Biomaterials Annual Meeting & Exposition on April 3-6, 2019 ... with academic, healthcare, governmental and business professionals in all aspects of the biomaterial ...
Breaking Biology News(10 mins):
(Date:3/19/2019)... ... 19, 2019 , ... The AACR annual conference pulls together a diverse group ... cutting-edge cancer research. The Visikol team will be at the show at booth #3252 ... well as their digital pathology services . “For AACR this year we are ...
(Date:3/19/2019)... (PRWEB) , ... March 19, 2019 , ... Bogey was nine years old when he ... in his left hip. These ailments caused Bogey to experience problems with his mobility. ... up stairs, and onto his special spot on the couch. , His owners, devastated at ...
(Date:3/19/2019)... ... ... will review strategies for data management in modular and adaptive clinical trials. , Participants ... to 30 percent, reducing cost while increasing quality, achieving clinical site set-up faster , ... – reducing risk and impact on trial success, trial teams, and trial execution , ...
(Date:3/19/2019)... ... March 19, 2019 , ... Cirrascale Cloud Services ®, ... begun offering NVIDIA® DGX-1™ deep learning systems as part of its dedicated, multi-GPU ... highest performance for artificial intelligence and deep learning research and development. , “Our ...
Breaking Biology Technology:
Cached News: